Vistagen Therapeutics Inc
VTGN2.868USD
-0.052-1.79%
Market hours （ET）Quotes delayed by 15 min
83.16MMarket Cap
LossP/E TTM
More Details of Vistagen Therapeutics Inc Company
Vistagen Therapeutics, Inc. is a neuroscience-focused biopharmaceutical company. The Company is engaged in the development and commercialization of therapies for psychiatric and neurological disorders based on its understanding of nose-to-brain neurocircuitry. Its clinical-stage pipeline consists of intranasal product candidates from a new class of potential neuroscience therapies called pherines. Its diversified pipeline of pherine product candidates rapidly activate chemosensory neurons in the nasal cavity to impact fundamental neurocircuitry in the olfactory system and the brain. Its pipeline also includes an oral prodrug with potential to modulate N-methyl-D-aspartate receptor (NMDA) receptor activity. Its neuroscience pipeline includes five clinical-stage investigational agent, namely Fasedienol (PH94B), Itruvone (PH10), AV-101, PH15, PH80, and PH284.
Company Info
Ticker SymbolVTGN
Company nameVistagen Therapeutics Inc
IPO dateOct 18, 2010
CEOMr. Shawn K. Singh, J.D.
Number of employees56
Security typeOrdinary Share
Fiscal year-endOct 18
Address343 Allerton Avenue
CitySOUTH SAN FRANCISCO
Stock exchangeNASDAQ Capital Market Consolidated
CountryUnited States of America
Postal code94080
Phone16505773600
Websitehttps://www.vistagen.com/
Ticker SymbolVTGN
IPO dateOct 18, 2010
CEOMr. Shawn K. Singh, J.D.
Company Executives
Name
Name/Position
Position
Shareholding
Change
Mr. Shawn K. Singh, J.D.
Mr. Shawn K. Singh, J.D.
Chief Executive Officer, Director
Chief Executive Officer, Director
38.90K
--
Dr. Jerry B. Gin, Ph.D.
Dr. Jerry B. Gin, Ph.D.
Independent Director
Independent Director
13.33K
--
Mr. Joshua S Prince
Mr. Joshua S Prince
Chief Operating Officer
Chief Operating Officer
10.86K
--
Mr. Jon S. Saxe, J.D.
Mr. Jon S. Saxe, J.D.
Independent Director
Independent Director
1.86K
--
Mr. Reid G. Adler, J.D.
Mr. Reid G. Adler, J.D.
Chief Legal Officer
Chief Legal Officer
--
--
Ms. Margaret M. (Maggie) Fitzpatrick
Ms. Margaret M. (Maggie) Fitzpatrick
Independent Chairman of the Board
Independent Chairman of the Board
--
--
Ms. Mary L. Rotunno
Ms. Mary L. Rotunno
Independent Director
Independent Director
--
--
Dr. Joanne Curley, Ph.D.
Dr. Joanne Curley, Ph.D.
Independent Director
Independent Director
--
--
Ms. Cynthia (Cindy) Anderson, CPA
Ms. Cynthia (Cindy) Anderson, CPA
Chief Financial Officer, Treasurer
Chief Financial Officer, Treasurer
--
--
Ms. Elissa Cote
Ms. Elissa Cote
Chief Corporate Development Officer
Chief Corporate Development Officer
--
--
View more
Name
Name/Position
Position
Shareholding
Change
Mr. Shawn K. Singh, J.D.
Mr. Shawn K. Singh, J.D.
Chief Executive Officer, Director
Chief Executive Officer, Director
38.90K
--
Dr. Jerry B. Gin, Ph.D.
Dr. Jerry B. Gin, Ph.D.
Independent Director
Independent Director
13.33K
--
Mr. Joshua S Prince
Mr. Joshua S Prince
Chief Operating Officer
Chief Operating Officer
10.86K
--
Mr. Jon S. Saxe, J.D.
Mr. Jon S. Saxe, J.D.
Independent Director
Independent Director
1.86K
--
Mr. Reid G. Adler, J.D.
Mr. Reid G. Adler, J.D.
Chief Legal Officer
Chief Legal Officer
--
--
Ms. Margaret M. (Maggie) Fitzpatrick
Ms. Margaret M. (Maggie) Fitzpatrick
Independent Chairman of the Board
Independent Chairman of the Board
--
--
Revenue Breakdown
No Data
No Data
By Business
By Region
No Data
Shareholding Stats
Updated: Fri, Jul 25
Updated: Fri, Jul 25
Shareholders
Shareholder Types
Shareholders
Shareholders
Proportion
TCG Crossover Management, LLC
8.96%
Nantahala Capital Management, LLC
6.63%
The Vanguard Group, Inc.
6.56%
StemPoint Capital LP
5.86%
Commodore Capital LP
5.27%
Other
66.71%
Shareholders
Shareholders
Proportion
TCG Crossover Management, LLC
8.96%
Nantahala Capital Management, LLC
6.63%
The Vanguard Group, Inc.
6.56%
StemPoint Capital LP
5.86%
Commodore Capital LP
5.27%
Other
66.71%
Shareholder Types
Shareholders
Proportion
Investment Advisor
25.72%
Hedge Fund
20.80%
Research Firm
3.01%
Investment Advisor/Hedge Fund
2.07%
Individual Investor
0.34%
Other
48.06%
Institutional Shareholding
Updated: Tue, Jul 1
Updated: Tue, Jul 1
Reporting Period
No. of institutions
Shares Held
Proportion
Change
2025Q2
119
15.51M
51.95%
-4.45M
2025Q1
178
15.52M
53.23%
-4.54M
2024Q4
189
15.27M
53.10%
-1.38M
2024Q3
188
15.00M
55.60%
-3.08M
2024Q2
215
16.08M
59.60%
-5.25M
2024Q1
231
17.00M
63.09%
-4.65M
2023Q4
242
17.28M
64.17%
+1.95M
2023Q3
236
3.11M
33.43%
-2.83M
2023Q2
238
1.09M
13.89%
-3.94M
2023Q1
249
1.40M
19.25%
-3.84M
View more
Shareholder Activity
Name
Shares Held
Proportion
Change
Chg %
Date
TCG Crossover Management, LLC
2.68M
9.18%
--
--
Mar 31, 2025
Nantahala Capital Management, LLC
1.98M
6.79%
-3.49K
-0.18%
Mar 31, 2025
The Vanguard Group, Inc.
1.96M
6.72%
-60.18K
-2.98%
Mar 31, 2025
StemPoint Capital LP
1.75M
6%
+38.06K
+2.22%
Mar 31, 2025
Commodore Capital LP
1.57M
5.4%
--
--
Mar 31, 2025
Sphera Funds Management Ltd.
790.55K
2.71%
-18.00K
-2.23%
Mar 31, 2025
J.P. Morgan Securities LLC
750.86K
2.58%
-21.37K
-2.77%
Mar 31, 2025
Ikarian Capital LLC
601.70K
2.06%
+524.09K
+675.23%
Mar 31, 2025
Diadema Partners LP
565.98K
1.94%
+123.45K
+27.90%
Mar 31, 2025
Adar1 Capital Management LLC
420.76K
1.44%
+299.30K
+246.42%
Mar 31, 2025
View more
Related ETFs
Updated: Sat, Aug 2
Updated: Sat, Aug 2
Name
Proportion
AdvisorShares Psychedelics ETF
4.67%
iShares Micro-Cap ETF
0.01%
iShares Neuroscience and Healthcare ETF
0%
Avantis US Small Cap Equity ETF
0%
AdvisorShares Psychedelics ETF
Proportion4.67%
iShares Micro-Cap ETF
Proportion0.01%
iShares Neuroscience and Healthcare ETF
Proportion0%
Avantis US Small Cap Equity ETF
Proportion0%
Dividend
A total of
0.00
USD has been distributed in dividends over the past 5 years.
Date
Dividend
Record Date
Payment Date
Ex-dividend Date
No Data
Stock Split
Date
Type
Ratio
Jun 06, 2023
Merger
30<1
Jun 06, 2023
Merger
30<1
Jun 06, 2023
Merger
30<1
Jun 06, 2023
Merger
30<1
Date
Type
Ratio
Jun 06, 2023
Merger
30<1
Jun 06, 2023
Merger
30<1
Jun 06, 2023
Merger
30<1
Jun 06, 2023
Merger
30<1
